Sterling Pharma and MIB partner to develop low-cost route to new oral COVID drug
![](/46/pdcnewsitem/11/55/41/HLN00CPO_Sterling_784x590.jpg)
The new route uses a novel enzyme, cytidine aminotransferase, which would reduce the manufacturing cost of the drug
Global CDMO Sterling Pharma Solutions and the University of Manchester Institute of Biotechnology (MIB) have formed a partnership to support the development of a novel, low-cost manufacturing route to molnupiravir — a new antiviral drug for the treatment of COVID-19.
From its facility in Dudley, Northumberland, the CDMO will provide chemical scale-up to multi-kilogrammes and process development services for Manchester University's project for which it has received grant funding from the Bill and Melinda Gates Foundation.
Although the drug was was originally developed by Ridgeback Biotherapeutics and Merck Sharp and Dohm, the new route has been developed by researchers at MIB, and includes the use of a novel enzyme, cytidine aminotransferase, which would reduce the manufacturing cost of the drug.
The process could allow generic pharmaceutical manufacturers to produce large-scale quantities of molnupiravir to supply of lower-income countries, subject to authorisation from further regulatory agencies, including the World Health Organization and national governments.
Molnupiravir, which has recently (4 November 2021) been approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of patients with COVID-19, is the first oral antiviral treatment for coronavirus that could be self-administered at home.
![Sterling Pharma Solutions](https://www.cphi-online.com/Sterling_PrimaryLogo-01%20(3)-comp264202.jpg)
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance